Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:IGMSNASDAQ:IMABNASDAQ:NRSNNASDAQ:STRO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIGMSIGM Biosciences$1.25+4.2%$1.21$0.92▼$22.50$74.72M0.61312,054 shs191,603 shsIMABI-Mab$0.99-5.7%$0.84$0.60▼$2.00$80.84M1.13308,177 shs184,463 shsNRSNNeuroSense Therapeutics$1.52+4.1%$1.08$0.51▼$1.63$20.77M1.36252,434 shs301,275 shsSTROSutro Biopharma$0.92+1.9%$0.78$0.52▼$5.17$77.70M1.771.10 million shs721,581 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIGMSIGM Biosciences+4.17%+5.93%-10.07%-9.42%-89.10%IMABI-Mab-5.71%+10.00%+16.68%+1.33%-43.75%NRSNNeuroSense Therapeutics+4.11%+15.15%+54.02%+39.45%+22.58%STROSutro Biopharma+1.93%+0.92%+2.22%-48.02%-78.40%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationIGMSIGM Biosciences4.2581 of 5 stars3.02.00.04.63.23.31.3IMABI-Mab2.962 of 5 stars3.75.00.00.01.81.70.6NRSNNeuroSense Therapeutics1.9953 of 5 stars3.55.00.00.00.01.70.0STROSutro Biopharma4.3869 of 5 stars4.13.00.04.72.71.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIGMSIGM Biosciences 1.90Reduce$5.50340.00% UpsideIMABI-Mab 3.33Buy$5.50455.56% UpsideNRSNNeuroSense Therapeutics 3.00Buy$14.00821.05% UpsideSTROSutro Biopharma 2.13Hold$6.11564.60% UpsideCurrent Analyst Ratings BreakdownLatest NRSN, IMAB, STRO, and IGMS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/19/2025STROSutro BiopharmaBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetUnderperform ➝ Underperform$1.00 ➝ $0.805/12/2025NRSNNeuroSense TherapeuticsD Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/12/2025NRSNNeuroSense TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$14.004/29/2025STROSutro BiopharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$2.00 ➝ $2.004/4/2025IMABI-MabHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$8.00 ➝ $7.004/4/2025IMABI-MabNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.00 ➝ $4.003/17/2025STROSutro BiopharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral$12.00 ➝ $2.003/14/2025STROSutro BiopharmaPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$2.003/14/2025STROSutro BiopharmaPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold3/14/2025STROSutro BiopharmaCitizens JmpSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Market Perform3/14/2025STROSutro BiopharmaWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Neutral$8.00 ➝ $2.00(Data available from 5/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIGMSIGM Biosciences$2.68M27.87N/AN/A$3.46 per share0.36IMABI-Mab$3.27M24.70N/AN/A$2.93 per share0.34NRSNNeuroSense TherapeuticsN/AN/AN/AN/A($0.14) per shareN/ASTROSutro Biopharma$66.43M1.17N/AN/A$2.45 per share0.38Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIGMSIGM Biosciences-$246.42M-$3.27N/AN/AN/A-7,534.03%-155.42%-61.04%N/AIMABI-Mab-$206.44MN/A0.00N/AN/AN/AN/AN/AN/ANRSNNeuroSense Therapeutics-$11.28M-$0.54N/A∞N/AN/AN/A-590.79%6/24/2025 (Estimated)STROSutro Biopharma-$106.79M-$2.98N/AN/AN/A-77.01%-101.89%-28.69%8/12/2025 (Estimated)Latest NRSN, IMAB, STRO, and IGMS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025IGMSIGM Biosciences-$0.41-$0.86-$0.45-$0.86$4.25 million$0.50 million5/8/2025Q1 2025STROSutro Biopharma-$0.63-$0.91-$0.28-$0.91$11.61 million$17.40 million4/7/2025Q4 2024NRSNNeuroSense Therapeutics-$0.12-$0.06+$0.06-$0.06N/AN/A3/13/2025Q4 2024STROSutro Biopharma-$0.86-$2.96-$2.10-$0.89$10.44 million$14.00 million3/6/2025Q4 2024IGMSIGM Biosciences-$0.74-$0.61+$0.13-$0.61$0.39 million$0.41 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthIGMSIGM BiosciencesN/AN/AN/AN/AN/AIMABI-MabN/AN/AN/AN/AN/ANRSNNeuroSense TherapeuticsN/AN/AN/AN/AN/ASTROSutro BiopharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIGMSIGM BiosciencesN/A5.225.22IMABI-MabN/A15.9915.99NRSNNeuroSense TherapeuticsN/A0.21N/ASTROSutro BiopharmaN/A3.093.09Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIGMSIGM Biosciences42.79%IMABI-Mab38.38%NRSNNeuroSense Therapeutics1.04%STROSutro Biopharma96.99%Insider OwnershipCompanyInsider OwnershipIGMSIGM Biosciences57.00%IMABI-Mab22.10%NRSNNeuroSense Therapeutics27.40%STROSutro Biopharma3.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableIGMSIGM Biosciences19059.78 million25.57 millionOptionableIMABI-Mab38081.66 million63.49 millionOptionableNRSNNeuroSense Therapeutics1013.67 million9.92 millionNot OptionableSTROSutro Biopharma24084.46 million77.59 millionOptionableNRSN, IMAB, STRO, and IGMS HeadlinesRecent News About These CompaniesSutro Biopharma, Inc. (NASDAQ:STRO) Given Consensus Rating of "Hold" by BrokeragesMay 24 at 1:29 AM | marketbeat.comPoint72 Asset Management L.P. Has $4.04 Million Stock Holdings in Sutro Biopharma, Inc. (NASDAQ:STRO)May 22 at 4:42 AM | marketbeat.com2,570,000 Shares in Sutro Biopharma, Inc. (NASDAQ:STRO) Purchased by Vestal Point Capital LPMay 21 at 8:23 AM | marketbeat.comBank of America Has Lowered Expectations for Sutro Biopharma (NASDAQ:STRO) Stock PriceMay 20, 2025 | americanbankingnews.comSuvretta Capital Management LLC Grows Position in Sutro Biopharma, Inc. (NASDAQ:STRO)May 19, 2025 | marketbeat.comMPM Bioimpact LLC Has $3.98 Million Position in Sutro Biopharma, Inc. (NASDAQ:STRO)May 16, 2025 | marketbeat.comSutro Biopharma (NASDAQ:STRO) Releases Earnings Results, Misses Expectations By $0.28 EPSMay 14, 2025 | marketbeat.comSutro Biopharma, Inc.: Sutro Biopharma Reports First Quarter 2025 Financial Results and Business HighlightsMay 9, 2025 | finanznachrichten.deSutro Biopharma, Inc. (STRO) Reports Q1 Loss, Tops Revenue EstimatesMay 8, 2025 | zacks.comSutro Biopharma Reports First Quarter 2025 Financial Results and Business HighlightsMay 8, 2025 | globenewswire.comSutro Biopharma (STRO) Expected to Announce Quarterly Earnings on MondayMay 7, 2025 | marketbeat.comSutro Biopharma to Participate in Upcoming Investor ConferencesMay 1, 2025 | globenewswire.comSutro Biopharma (NASDAQ:STRO) Given Neutral Rating at HC WainwrightMay 1, 2025 | marketbeat.comSutro Biopharma, Inc. (NASDAQ:STRO) Receives Average Recommendation of "Hold" from AnalystsApril 28, 2025 | marketbeat.comWhy Sutro Biopharma, Inc.’s (STRO) Stock Is Down 21.92%April 26, 2025 | aaii.comWhy Sutro Biopharma, Inc.’s (STRO) Stock Is Down 10.88%April 1, 2025 | aaii.comWhy Sutro Biopharma, Inc.’s (STRO) Stock Is Up 15.10%March 18, 2025 | aaii.comSutro Biopharma downgraded to Neutral from Buy at H.C. WainwrightMarch 17, 2025 | markets.businessinsider.comHC Wainwright & Co. Downgrades Sutro Biopharma (STRO)March 17, 2025 | msn.comSutro Biopharma presents expanded data from REFRalphaME-01 trialMarch 17, 2025 | markets.businessinsider.comSutro Biopharma Presents Data from Dose-Optimization Portion of REFRaME-O1 Trial in Patients with Platinum Resistant Ovarian Cancer at SGO 2025March 15, 2025 | tmcnet.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesD-Wave Pushes Back on Short Seller Case With Strong EarningsBy Nathan Reiff | May 14, 2025View D-Wave Pushes Back on Short Seller Case With Strong EarningsPalantir’s Latest Deal Could Put a Freeze on Its Stock PriceBy Chris Markoch | May 12, 2025View Palantir’s Latest Deal Could Put a Freeze on Its Stock PriceIf the U.S.-China Trade Reset Holds, These 3 Stocks Could FlyBy Chris Markoch | May 16, 2025View If the U.S.-China Trade Reset Holds, These 3 Stocks Could FlyArcher Rebuts Short Seller, Points to Strong Q1 & Global MomentumBy Jeffrey Neal Johnson | May 22, 2025View Archer Rebuts Short Seller, Points to Strong Q1 & Global MomentumAfter Earnings Beats, These 3 Stocks Are on Analysts’ RadarsBy Leo Miller | May 20, 2025View After Earnings Beats, These 3 Stocks Are on Analysts’ RadarsNRSN, IMAB, STRO, and IGMS Company DescriptionsIGM Biosciences NASDAQ:IGMS$1.25 +0.05 (+4.17%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$1.25 +0.00 (+0.40%) As of 05/23/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.IGM Biosciences, Inc., a clinical-stage biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer and autoimmune and inflammatory diseases. It develops Aplitabart, a Death Receptor 5 Agonist IgM antibody for the treatment of colorectal cancer; imvotamab, a CD20 x CD3 bispecific IgM antibody to treat myositis, as well as for the treatment of systemic lupus erythematosus and rheumatoid arthritis that is Phase Ib clinical trial; and IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of autoimmune diseases. IGM Biosciences, Inc. has a collaboration and license agreement with Genzyme Corporation to generate, develop, manufacture, and commercialize IgM antibodies. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.I-Mab NASDAQ:IMAB$0.99 -0.06 (-5.71%) Closing price 05/23/2025 03:58 PM EasternExtended Trading$0.97 -0.02 (-2.02%) As of 05/23/2025 07:03 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics in the fields of immuno-oncology and immuno-inflammation diseases primarily in the United States. It is developing Uliledlimab, a CD73 neutralizing antibody, which is in Phase 2 clinical trial for the treatment of solid tumors; Givastomig, a bi-specific antibody that is in Phase 1 clinical trial for the treatment of gastric and other cancers; and Ragistomig, a programmed cell death ligand-based tumor-dependent T cell engager, which is in Phase 1 clinical trial for the treatment of for solid tumors. The company is also evaluating opportunities to develop Lemzoparlimab, a fully human CD47 monoclonal antibody for cancer immunotherapy. It has strategic licensing agreement with Ferring International Center SA to research, develop, make, have made, import, use, sell and offer to sell FE301, an interleukin-6 inhibitor. The company has clinical collaboration with Bristol Myers Squibb to evaluate Claudin 18.2 x 4-1BB bispecific antibody givastomig in combination with nivolumab and chemotherapy for the treatment of gastric and esophageal cancer. I-Mab was founded in 2014 and is headquartered in Rockville, Maryland.NeuroSense Therapeutics NASDAQ:NRSN$1.52 +0.06 (+4.11%) Closing price 05/23/2025 03:59 PM EasternExtended Trading$1.54 +0.02 (+1.64%) As of 05/23/2025 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. The company was incorporated in 2017 and is headquartered in Herzliya, Israel.Sutro Biopharma NASDAQ:STRO$0.92 +0.02 (+1.93%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$0.91 -0.01 (-1.52%) As of 05/23/2025 06:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Sutro Biopharma, Inc. operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer. The company's pre-clinical product candidates include STRO-003, an ADC directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) for the treatment of solid tumors and hematological cancers; and STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including cervical, lung, and breast cancer. Sutro Biopharma, Inc. has collaboration and license agreements with Merck Sharp & Dohme Corporation to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; Vaxcyte to discover and develop vaccine candidates for the treatment or prophylaxis of infectious diseases; Tasly Biopharmaceuticals Co., Ltd. to develop and commercialize STRO-002 in Greater China; EMD Serono to develop ADCs for multiple cancer targets; and Astellas Pharma Inc. to develop immunostimulatory ADC. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/19 - 05/23 Trade Desk Silences Critics; Recovery Looks Poised to Continue Booz Allen Hamilton Earnings: 3 Bullish Signals for BAH Stock Turbulence for Joby Shares: What's Behind the Recent Dip? Pfizer's 7.5% Dividend: Income Haven or House of Cards? TJX Stock Price Stumble Is Your Chance to Pick Up a Bargain These ETFs Provide Easy Exposure to Growing International Markets Advance Auto Parts Jumps on Surprise Earnings Beat Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
